FDA Announces Public Advisory Committee Meeting on Psychopharmacologic Drugs and Drug Safety

Summary

The FDA is hosting a joint meeting of its Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee to provide advice on regulatory issues, with a public docket for comments and a forthcoming meeting open to the public.